Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Manganum Phosphoricum
Brand Name
Manganum Phosphoricum
Generic Name
Manganum Phosphoricum
Active Ingredient
Manganese Phosphate, DibasicCategory
Calculi Dissolution Agent [EPC]
Variants
8
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 1 [hp_Q]/1 | PELLET | ORAL | 37662-1552 |
| 1 [hp_M]/1 | PELLET | ORAL | 37662-1551 |
| 6 [hp_C]/1 | PELLET | ORAL | 37662-1545 |
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Manganum Phosphoricum, you must consult a qualified healthcare professional.
| 12 [hp_C]/1 | PELLET | ORAL | 37662-1546 |
| 200 [hp_C]/1 | PELLET | ORAL | 37662-1549 |
| 30 [hp_C]/1 | PELLET | ORAL | 37662-1547 |
| 100 [hp_C]/1 | PELLET | ORAL | 37662-1548 |
| 500 [hp_C]/1 | PELLET | ORAL | 37662-1550 |
Detailed information about Manganum Phosphoricum
Manganese Phosphate, Dibasic is a multi-functional therapeutic agent primarily classified as a Calculi Dissolution Agent. It is utilized in complex metabolic management to address mineral imbalances and inflammatory pathways.
For the management of renal calculi (kidney stones), the standard adult dosage of Manganese Phosphate, Dibasic typically ranges from 250 mg to 750 mg per day, divided into two or three doses. Healthcare providers often start with a lower dose to assess gastrointestinal tolerance before titrating (adjusting) upward based on urinary pH targets and stone dissolution progress. For chronic maintenance and prevention of stone recurrence, a lower dose of 125 mg to 250 mg once daily may be sufficient.
The safety and efficacy of Manganese Phosphate, Dibasic in pediatric populations have not been as extensively documented as in adults. However, when prescribed by a pediatric specialist, dosing is strictly weight-based. A common range is 2 mg to 5 mg per kilogram of body weight per day, divided into two doses. It is generally not recommended for children under the age of 6 unless the benefit clearly outweighs the risks of potential growth plate interference due to mineral modulation.
In patients with mild to moderate renal impairment (CrCl 30-60 mL/min), no initial dose adjustment is usually required, but frequent monitoring of serum phosphate and manganese levels is mandatory. For patients with severe renal impairment (CrCl < 30 mL/min) or those on dialysis, Manganese Phosphate, Dibasic is generally contraindicated or used at a significantly reduced dose (e.g., 50% of the standard dose) due to the risk of mineral accumulation and toxicity.
Since the liver is the primary route for manganese excretion, patients with hepatic impairment (liver disease) require cautious dosing. In cases of Child-Pugh Class B or C cirrhosis, healthcare providers may reduce the frequency of dosing to once every 48 hours to prevent systemic accumulation.
Geriatric patients often have a natural decline in renal and hepatic reserve. Dosing in the elderly should start at the lowest end of the spectrum (e.g., 125 mg daily) and be monitored closely for signs of mineral imbalance or cognitive changes.
To ensure maximum efficacy and safety, patients should adhere to the following guidelines:
If you miss a dose of Manganese Phosphate, Dibasic, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this significantly increases the risk of acute mineral toxicity.
Signs of an overdose of Manganese Phosphate, Dibasic may include severe nausea, vomiting, abdominal cramping, confusion, tremors (shaking), or an irregular heartbeat. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment typically involves gastric lavage (stomach pumping) and intravenous fluids to support renal excretion.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this may lead to a rapid recurrence of symptoms or stone formation.
Most patients taking Manganese Phosphate, Dibasic experience mild side effects that often diminish as the body adjusts to the medication. Common symptoms include:
Manganese Phosphate, Dibasic is a potent metabolic modulator. It is essential that patients undergo a full diagnostic workup, including 24-hour urine collection and blood chemistry panels, before starting treatment. This medication is not a 'one-size-fits-all' solution for kidney or gallstones and must be tailored to the specific chemical composition of the stones being treated.
No FDA black box warnings for Manganese Phosphate, Dibasic have been issued as of 2026. However, clinical guidelines emphasize the risk of neurological toxicity (manganism) if the drug is taken in doses exceeding the recommended range for extended periods.
Certain medications must never be used in combination with Manganese Phosphate, Dibasic due to the risk of severe adverse reactions:
Manganese Phosphate, Dibasic must NEVER be used in the following circumstances:
Manganese Phosphate, Dibasic is classified as FDA Pregnancy Category C. There are no adequate, well-controlled studies in pregnant women. Animal studies have suggested that high doses of manganese can cross the placenta and potentially affect fetal neurological development. Furthermore, its androgenic and NSAID-like properties could theoretically interfere with fetal circulation (e.g., premature closure of the ductus arteriosus) if used in the third trimester. It should be used during pregnancy only if the clinical need is urgent and no safer alternatives exist.
Manganese is a normal constituent of human milk; however, supplemental Manganese Phosphate, Dibasic can significantly increase concentrations. While the risk to the nursing infant is considered low at standard doses, the potential for altered mineral absorption in the infant exists. Healthcare providers may recommend monitoring the infant's growth and developmental milestones or temporarily suspending breastfeeding if high doses are required.
As noted in the dosage section, use in children is generally restricted to specialized metabolic clinics. The primary concern in pediatric populations is the effect of mineral chelation on growing bones and the potential for premature epiphyseal closure (stopping of bone growth) due to the drug's androgenic properties. Long-term safety data for children are currently lacking.
Manganese Phosphate, Dibasic exerts its therapeutic effect through a complex interaction with mineralized tissues and cellular receptors. The dibasic phosphate ion acts as a buffer in the urinary tract, creating an acidic environment that increases the solubility of calcium oxalate and calcium phosphate stones. Simultaneously, the manganese ion acts as a cofactor for several enzymes but also functions as a competitive inhibitor of calcium binding in crystalline structures.
Furthermore, the drug's Adrenergic Agonist activity stimulates G-protein coupled receptors, leading to an increase in intracellular cyclic AMP (cAMP), which promotes smooth muscle relaxation in the urogenital tract. Its Cyclooxygenase (COX) inhibition reduces the inflammatory response of the epithelial lining to stone-induced trauma.
The onset of action for urinary acidification is relatively rapid, occurring within 2-4 hours of the first dose. However, the physical dissolution of pre-existing calculi is a slow process, often requiring 3 to 6 months of continuous therapy to show significant changes on imaging (X-ray or Ultrasound). Tolerance to the adrenergic effects may develop over time, but the mineral-modulating effects remain consistent with long-term use.
Common questions about Manganum Phosphoricum
Manganese Phosphate, Dibasic is primarily used as a Calculi Dissolution Agent to help break down and dissolve kidney stones and gallstones. It works by binding to calcium within the stones and adjusting the acidity of body fluids to make minerals more soluble. Additionally, it has anti-inflammatory and anti-coagulant properties that help reduce the pain and irritation associated with stones. Your doctor may also prescribe it for specific mineral deficiencies or metabolic imbalances. It is a specialized medication that requires careful medical supervision and regular blood tests.
The most common side effects include gastrointestinal issues such as nausea, bloating, diarrhea, and a metallic taste in the mouth. Some patients also report mild skin flushing or headaches during the first few weeks of treatment. Dizziness, especially when standing up quickly, is also frequently noted due to the drug's effect on blood vessels. Most of these symptoms are mild and tend to resolve as your body becomes accustomed to the medication. However, if these effects persist or become bothersome, you should consult your healthcare provider for a dosage adjustment.
It is strongly recommended that you avoid or strictly limit alcohol consumption while taking Manganese Phosphate, Dibasic. Alcohol can irritate the stomach lining, which, when combined with the drug's NSAID-like properties, increases the risk of ulcers or gastrointestinal bleeding. Furthermore, alcohol can strain the liver, potentially interfering with the body's ability to clear manganese and increasing the risk of toxicity. Alcohol may also dehydrate the body, which can counteract the drug's goal of dissolving kidney stones. Always discuss your lifestyle habits with your doctor before starting this treatment.
Manganese Phosphate, Dibasic is generally not recommended during pregnancy unless the potential benefits significantly outweigh the risks to the fetus. It is classified as FDA Category C, meaning animal studies have shown potential harm, but human data is limited. There are concerns that high levels of manganese could affect fetal brain development or that the drug's hormonal effects could interfere with the pregnancy. If you are pregnant or planning to become pregnant, you must inform your doctor immediately. They will likely explore safer alternatives for managing your condition during this time.
While the chemical effects on your blood and urine chemistry begin within hours, the physical dissolution of stones is a very slow process. Most patients will not see a reduction in stone size on an ultrasound or CT scan for at least 3 to 6 months. Relief from inflammatory pain may occur sooner, typically within the first few weeks of consistent dosing. It is crucial to continue taking the medication exactly as prescribed, even if you do not feel immediate results. Your doctor will use regular imaging and lab tests to track the drug's progress over time.
No, you should not stop taking Manganese Phosphate, Dibasic suddenly without consulting your doctor. Abruptly ending the medication can cause a 'rebound effect,' where the concentration of stone-forming minerals in your urine increases rapidly, potentially leading to new stone formation or acute pain. Your healthcare provider will usually recommend a gradual tapering of the dose to allow your metabolism to adjust. If you are experiencing severe side effects, contact your doctor for an urgent evaluation rather than simply stopping the drug on your own. Consistent dosing is key to the long-term success of the treatment.
If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed one and continue with your regular routine. Do not take two doses at once to make up for the missed one, as this can lead to an acute spike in mineral levels and increase the risk of side effects. Setting a daily alarm or using a pill organizer can help you stay consistent with your schedule. If you frequently miss doses, talk to your doctor about strategies to improve adherence, as consistency is vital for stone dissolution.
Weight gain is not a commonly reported side effect of Manganese Phosphate, Dibasic. However, because the drug has some androgenic (hormone-like) properties, some patients might experience changes in body composition or fluid retention, which can feel like weight gain. If you notice rapid weight gain, swelling in your ankles or feet, or a significant increase in appetite, you should report these symptoms to your doctor. These could be signs of a metabolic change or a reaction to the medication that needs to be addressed. In most cases, any weight changes are minimal and manageable with diet and exercise.
Manganese Phosphate, Dibasic has several significant drug interactions, so it must be used cautiously with other medications. It can interfere with the absorption of certain antibiotics and can have dangerous interactions with Parkinson's disease medications like Levodopa. It also interacts with other mineral supplements, particularly calcium and iron, which can bind to the drug and make it less effective. You must provide your doctor with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking. Your pharmacist can also help check for potential interactions before you start a new medication.
Yes, Manganese Phosphate, Dibasic is available as a generic medication, which is typically more cost-effective than brand-name versions. Generic formulations are required by the FDA to have the same active ingredient, strength, and efficacy as the brand-name drug. However, the inactive ingredients (fillers and binders) may vary between manufacturers, which can occasionally affect how well a patient tolerates the pill. If you have specific allergies to dyes or fillers, check with your pharmacist about the generic version being dispensed. Most insurance plans cover the generic form of this medication.
While rare, some side effects require urgent intervention. Stop taking the medication and call your doctor immediately if you experience:
> Warning: Stop taking Manganese Phosphate, Dibasic and call your doctor immediately if you experience any of these serious symptoms. Early intervention is critical to preventing long-term complications.
Prolonged use of Manganese Phosphate, Dibasic (greater than 6-12 months) requires careful monitoring. Potential long-term effects include:
As of the 2026 FDA update, there are no specific Black Box Warnings for Manganese Phosphate, Dibasic. However, the FDA emphasizes that this drug should only be used in patients with confirmed metabolic or calculous disease and should never be used as a general mineral supplement.
Report any unusual symptoms or changes in your health to your healthcare provider promptly. Keeping a symptom diary can help your doctor determine if your side effects are related to the medication or another underlying condition.
Patients on Manganese Phosphate, Dibasic require regular clinical monitoring to ensure safety and efficacy. This typically includes:
Manganese Phosphate, Dibasic may cause dizziness or mild blurred vision in some patients, especially during the first few days of treatment. Do not drive, operate heavy machinery, or engage in hazardous activities until you know how this medication affects you.
Alcohol should be avoided or strictly limited while taking Manganese Phosphate, Dibasic. Alcohol can increase the risk of gastrointestinal irritation and may interfere with the liver's ability to process manganese, increasing the risk of toxicity.
Do not stop taking Manganese Phosphate, Dibasic abruptly unless directed by your doctor. Sudden discontinuation can lead to a 'rebound' effect where urinary mineral concentrations spike, potentially causing the rapid formation of new stones. Your healthcare provider will typically provide a tapering schedule to slowly reduce the dose.
> Important: Discuss all your medical conditions, including any history of liver disease, kidney disease, or neurological disorders, with your healthcare provider before starting Manganese Phosphate, Dibasic.
Manganese Phosphate, Dibasic can interfere with certain diagnostic tests:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication reconciliation is the best way to prevent dangerous drug interactions.
Conditions requiring a careful risk-benefit analysis include:
Patients who have had severe allergic reactions to other manganese-containing compounds (such as Manganese Sulfate) or other dibasic phosphate salts should avoid this medication, as there is a high likelihood of cross-reactivity.
> Important: Your healthcare provider will evaluate your complete medical history, including laboratory values and imaging, before prescribing Manganese Phosphate, Dibasic to ensure it is safe for you.
Patients over age 65 are at a higher risk for adverse effects. Reduced renal clearance can lead to phosphate accumulation, while age-related changes in the blood-brain barrier may make the elderly more susceptible to the neurological side effects of manganese. Dose titration should be slow, and cognitive function should be monitored at every follow-up visit.
In patients with a GFR (Glomerular Filtration Rate) between 30 and 50 mL/min, the dose should be reduced by 25-50%. If GFR falls below 30 mL/min, the drug should generally be discontinued. Dialysis does not effectively remove manganese, though it does remove phosphate; therefore, patients on dialysis are at high risk for manganese toxicity even if phosphate levels are controlled.
For patients with significant liver dysfunction (Child-Pugh Class B or C), the drug is often avoided. If used, LFTs and serum manganese levels must be checked weekly. Any sign of worsening encephalopathy (brain dysfunction due to liver failure) is an indication to stop the drug immediately.
> Important: Special populations require individualized medical assessment and more frequent laboratory monitoring than the general population.
| Parameter | Value |
|---|---|
| Bioavailability | 35% - 45% |
| Protein Binding | 60% (Primarily Albumin) |
| Half-life | 12 - 18 hours |
| Tmax | 2 - 3 hours |
| Metabolism | Hepatobiliary (Non-CYP) |
| Excretion | Fecal 70%, Renal 30% |
Manganese Phosphate, Dibasic is a member of the Calculi Dissolution Agent class. It is chemically related to other phosphate salts but is unique due to the inclusion of manganese, which provides its distinct adrenergic and anti-inflammatory properties.